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Summary
 
Hematopoietic progenitor cells migrate in vitro and in vivo towards a gradient of the chemo-
tactic factor stromal cell-derived factor-1 (SDF-1) produced by stromal cells. This is the first
chemoattractant reported for human CD34
 
1
 
 progenitor cells. Concentrations of SDF-1 that elicit
chemotaxis also induce a transient elevation of cytoplasmic calcium in CD34
 
1
 
 cells. SDF-1-induced
chemotaxis is inhibited by pertussis toxin, suggesting that its signaling in CD34
 
1
 
 cells is medi-
ated by seven transmembrane receptors coupled to G
 
i
 
 proteins. CD34
 
1
 
 cells migrating to SDF-1
include cells with a more primitive (CD34
 
1
 
/CD38
 
2
 
 or CD34
 
1
 
/DR
 
2
 
) phenotype as well as
CD34
 
1
 
 cells phenotypically committed to the erythroid, lymphoid and myeloid lineages, in-
cluding functional BFU-E, CFU-GM, and CFU-MIX progenitors. Chemotaxis of CD34
 
1
 
cells in response to SDF-1 is increased by IL-3 in vitro and is lower in CD34
 
1
 
 progenitors
from peripheral blood than in CD34
 
1
 
 progenitors from bone marrow, suggesting that an al-
tered response to SDF-1 may be associated with CD34 progenitor mobilization.
 
E
 
ntrance and exit of hematopoietic progenitor cells
(HPC)
 
1
 
 to or from the bone marrow (BM) takes place
during transplantation or mobilization of CD34
 
1
 
 progeni-
tor cells, two procedures routinely used in the clinic today.
For successful transplantation, donor HPC are given in-
travenously and must subsequently home to the BM. Con-
versely, during chemotherapy and/or growth factor–induced
mobilization of BM progenitors, HPC increase 10–200-fold
in the blood (1–4). The mechanisms and specific molecules
involved in the experimental mobilization of HPC from
the BM into peripheral blood (PB) or in the homing of
HPC and in their trafficking through the BM are still un-
clear, but they might be similar to those utilized by HPC to
recirculate and migrate during their maturation.
HPC in the BM are thought to be located within spe-
cific stroma niches (5). These specific environments pro-
vide soluble factors and cellular interactions required for
HPC proliferation and differentiation. As HPC differenti-
ate, they may move from one type of niche to another (6–8).
In addition to their movement within the BM, HPC pre-
sumably move out from this organ as indicated by the de-
tection of HPC in the PB of normal untreated adults (
 
z
 
1%
of the number present in the BM) (9, 10). Whether HPC
circulate across, exit, or remain sessile within a BM niche
may ultimately depend on the type and function of cell ad-
hesion receptors on their surface.
It is well established that the function of adhesion mole-
cules on the surface of leukocytes is critically regulated by
activating events triggered by chemoattractants binding to
specific receptors on the leukocytes. These activation events
allow them to stick firmly to and, eventually, to emigrate
through the vessel wall into the extravascular spaces (11–13).
Leukocytes are ultimately attracted to extravascular sites via
the generation of chemotactic gradients. Chemoattractants
for HPC have not been described so far. Cells of the hema-
topoietic microenvironment (stromal cells) are ideal candi-
dates for producing chemoattractants that could be involved
in the homing, retention, and exit of HPC in hematopoie-
tic organs.
In this report, we provide evidence that human CD34
 
1
 
HPC are attracted by stromal cell-derived factor-1 (SDF-1),
 
1
 
Abbreviations used in this paper:
 
 BM, bone marrow; CFC, colony-forming
cell; FL, fetal liver; G-CSF, granulocyte–colony-stimulating factor; HPC,
hematopoietic progenitor cells; HS, Hepes-buffered saline; MCP, mac-
rophage chemotactic protein; MIP, macrophage inflammatory protein;
PBPC, peripheral blood progenitor cell; PI, propidium iodide; SDF, stro-
mal cell-derived factor.
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a chemoattractant produced by BM stromal cells. The
chemotactic response to SDF-1 is lower in CD34
 
1
 
 HPC
from PB collections than in CD34
 
1
 
 HPC from BM collec-
tions, suggesting that an altered response to SDF-1 may be
associated with HPC mobilization.
 
Materials and Methods
 
PBPC Collections.
 
Mobilized PBPCs were collected by leu-
kapheresis from seven patients being treated on protocols at the
Dana-Farber Cancer Institute (14). Donor patients were being
treated for advanced breast cancer (
 
n
 
 
 
5
 
 6) or non-Hodgkin’s
lymphoma (
 
n
 
 
 
5
 
 1) (stage III to stage IV). Mobilization regimens
consisted of single-agent doxorubicin 90 mg/m
 
2
 
 (
 
n
 
 
 
5
 
 3) or cy-
clophosphamide 6 g/m
 
2
 
 (
 
n
 
 
 
5
 
 3) followed in either case by sub-
cutaneous injection of 5 
 
m
 
g/kg of granulocyte–colony-stimulat-
ing factor (G-CSF) daily for 5 d (Neupogen, Amgen, Thousand
Oaks, CA). PBPCs were collected on consecutive days at the
time of hematological recovery after the chemotherapy-induced
leukopenia. One patient had PBPC, collected at the beginning
the fifth day of G-CSF treatment (5 
 
m
 
g/kg), which was given
daily by subcutaneous injection without chemotherapy (labeled as
a diamond in Fig. 4). PBPCs used in this study were all obtained
from different subjects and from products collected either on the
first (
 
n
 
 
 
5
 
 1), second (
 
n
 
 
 
5
 
 4), or third (
 
n
 
 
 
5
 
 3) day of leukapheresis.
All samples were obtained from the Dana Farber Cancer Institute
blood component laboratory with the exception of one set of BM
or PB from the same patient which was obtained from the hematol-
ogy/oncology staff of The Hospital Universitario de Alcala and The
Centro Ramon y Cajal (Madrid, Spain).
All leukapheresis procedures were performed using the Cobe
Spectra (Lakewood, CO) cell separator. Colony-forming unit–
cell (CFC) assays were performed on all leukapheresis compo-
nents using methylcellulose-based media with recombinant cy-
tokines (Stem Cell Technologies, Vancouver, Canada) to control
for the presence of HPC in the PBPC. Colonies were classified as
CFU-GM, CFU-MIX, and BFU-E colonies according to stan-
dardized morphologic criteria, as previously described (14). The
average content in CFC per 10
 
6
 
 MNC from the leukapheresis
used in this study were the following: CFU-GM, 5.1 
 
3
 
 10
 
5
 
 (SD
3.3), CFU-MIX 8.2 
 
3
 
 10
 
4
 
 (SD 6.3), and BFU-E 4.5 
 
3
 
 10
 
5
 
 (SD
1.2), respectively.
 
BM and Umbilical Cord Blood Samples.
 
Umbilical cord blood
(CB) was collected following normal deliveries at the Brigham
and Women’s Hospital according to institutional guidelines for
discarded material (protocol no. 92-5142-02). BM was collected
from normal donors (
 
n
 
 
 
5
 
 6) and from one patient with breast
cancer at the time of harvest for allogeneic or autologous trans-
plantation at the Dana-Farber Cancer Institute (labeled as a square
in Fig. 4).
 
Purification of CD34
 
1
 
 Cells.
 
CD34
 
1
 
 cell selection was per-
formed by immunoadsorption using the CellPro (Bothell, WA)
Ceprate LC system as follows. CB, BM, or PB samples were di-
luted 1:2 with PBS containing sodium citrate 0.6%, 1% FCS
(JRH Biosciences, Lenexa, KS), then layered onto Histopaque-
1077 (Sigma Chemical Co., St. Louis, MO) and centrifuged at
400 
 
g
 
 for 30 min. After collecting the mononuclear interface, the
cells were incubated with a biotinylated mAb to CD34 (8G12),
washed three times with PBS, 0.2% BSA, and purified using the
immunoaffinity column (Ceprate-LC34; CellPro), according to
manufacturer’s instructions. After elution, cells were washed twice
in IMDM (Biowhittaker, Walkersville, MD). Purity of the
CD34
 
1
 
 cell-enriched fraction ranged between 85–95% for CB
samples, and between 90–95% for BM and PB preparations. The
cloning efficiency for CD34
 
1
 
 cells in a CFC was, on average, 8%
for BM cells, 9.5% for mobilized PB cells, and 14% for CB cells.
 
Stromal Cell–conditioned Media and Purification of SDF-1.
 
Conditioned media from BM-derived mouse stromal cell lines
MS-5 (gift from Professor K.J. Mori, Kyoto, Japan) (15), CBR-
BM,D
 
'
 
1, CBR-BM,L
 
'
 
21, CBR-BM,D
 
'
 
10, CBR-BM,L
 
'
 
19
(16), or NIH-3T3 embryonic BM fibroblasts, were grown in
IMDM 10% FCS until confluent. The medium was replaced
with serum-free medium (Ultraculture, Biowhittaker), collected
after 4–5 d of culture, and passed though a 0.45-
 
m
 
m filter.
The SDF-1 was purified from conditioned medium of the
MS-5 cell line as described in detail elsewhere (17). In brief, the
conditioned media was passed through a 0.22 
 
m
 
m filter and ap-
plied to a 5 ml HiTrap heparin column (Pharmacia) on the Phar-
macia FPLC system. Active material was eluted from the column
with a linear gradient of NaCl (0.4–2.0 M) and then applied to a
1 ml SP Sepharose HP cation exchange column (Pharmacia). Ac-
tive fractions were then eluted with a linear gradient of NaCl
(0.15–1.0 M) and applied to a Vydac C4 reverse-phase HPLC
column (Vydac, Hesperia, CA). Active material eluted as a single
peak with an acetonitrile gradient (0–80%) in trifluoroacetic acid,
was lyophilized and resuspended in 10 mM sodium phosphate,
pH 7.3, 150 mM NaCl. The purified protein migrated as a single
band in SDS-PAGE of 8 kD. The protein was identified as SDF-1
by NH
 
2
 
-terminal amino acid sequencing, amino acid composi-
tion, and mass spectrometry (17). SDF-1 protein concentration
was determined using a BCA protein assay (Pierce).
 
Chemokines and Cytokines.
 
For chemotactic assays, the fol-
lowing chemokines obtained from Peprotec were used at the in-
dicated optimal concentration: human macrophage inflammatory
protein-1 (MIP-1) 
 
a
 
 and 
 
b
 
 (50 ng/ml), human and mouse mac-
rophage chemotactic protein-1 (MCP-1) (25 ng/ml), eotaxin
(100 ng/ml), RANTES (50 ng/ml), IL-8 (25 ng/ml). Human
stem cell factor (gift from Immunex) was used at 100 ng/ml.
 
Chemotactic Assays.
 
All assays were performed in duplicate us-
ing 5-
 
m
 
m pore filters (Transwell, 24-well cell clusters; Costar,
Boston, MA). For transendothelial migration assays, 2 
 
3
 
 10
 
4
 
 cells
of the mouse endothelial cell line b-End-3 (18) were layered on
the filters and grown in 10% FCS IMDM for 2 d before the per-
formance of each assay. Immediately before each assay, bare filters
or endothelial cell–covered filters were rinsed in serum-free me-
dia and the supernatant was aspirated. 1.5 
 
3
 
 10
 
5
 
 CD34
 
1
 
 cells in
100 
 
m
 
l were loaded into each Transwell filter. Filters were then
carefully transferred to another well containing 600 
 
m
 
l dilutions
of supernatant (1:2) or purified chemokines in serum-free media,
previously incubated for 15 min at 37
 
8
 
C in 7.5% CO
 
2
 
. After 3.5 h,
the upper chamber was carefully removed and the cells in the
bottom chamber resuspended and divided in aliquots for FACS
 
Ò
 
analysis (cell counting and immunophenotyping) and CFC assays.
10% of the input cell population (1.5 
 
3
 
 10
 
4
 
) was also seeded in
duplicate wells in 600 
 
m
 
l of serum-free media for the same period
of time (but not subjected to any chemotaxis assay) to be used as
control for FACS
 
Ò
 
 counting.
Results obtained with transendothelial chemotaxis assays using
the b-End-3 cell line were similar to those obtained in a limited
series of experiments using HUVECS to coat the transwell inserts
(data not shown).
 
Cell Counting and Immunophenotyping of CD34
 
1
 
 Populations.
 
For determination of the proportion of CD34
 
1
 
 cells that showed
a chemotactic response, migrating cells (recovered from the lower
chamber) were labeled with anti-CD34 PE (Becton Dickinson, 
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Mountain View, CA) and anti-CD45 FITC (Dako, Carpinteria,
CA) mAbs and analyzed in parallel from duplicate wells. CD34
 
1
 
cells were defined as positive events in the low SSC region,
CD34
 
1
 
/CD45
 
dull
 
 windows. To obtain absolute values of migra-
tory cells, flow cytometric counts for each sample were obtained
during a constant, predetermined period of time and were com-
pared with duplicate flow cytometric counts obtained from the
control wells that were set up with 10% of the input population
and were not subjected to chemotaxis assays. Data were expressed
as a percentage of the input population or as chemotactic index
(the ratio between the cells that migrated to the chemotactic
stimuli and the cells that migrated to the control media). For im-
munophenotyping, cells from chemotaxis assays were labeled
with anti-CD34 PE and either anti-CD38 FITC, anti-CD45RA
FITC, anti-CD33 FITC (from Dako), anti-HLA-DR FITC, anti-
CD10 FITC (Becton Dickinson), and analyzed by flow cytome-
try. All stainings were performed on ice, for 25 min, in PBS con-
taining 3% FCS, 1% BSA (Sigma), 0.1% sodium azide in 96-well
V-bottomed plates. Propidium iodide (PI) (Sigma) to 1 
 
m
 
g/ml was
added to each sample before the analysis. Samples were collected
on a FACScan
 
Ò
 
 flow cytometer (Becton Dickinson) and data was ac-
quired in listmode with Cell Quest software (Becton Dickinson).
 
Assay for CFC.
 
Appropriate amounts of cells from the che-
motaxis assays were plated in duplicate in 1 ml methylcellulose as-
say–based media (19) containing 2.5 U/ml rHu erythropoietin
(R.W. Johnson Pharma Research Institute, Springhouser, PA),
150 ng/ml rHu stem cell factor, 200 U/ml rHu IL-3, 40 ng/ml of
PIXY321, (all gift of Immunex, Seattle, WA). Colonies were
scored for CFU-GM, CFU-MIX, and BFU-E after incubation at
37
 
8
 
C, 5% CO
 
2
 
. The total number of CFC present in the sample
was calculated by multiplying for the fraction of the migrated cells
analyzed in the CFC assay.
 
In Vivo Migration of Transplanted FDCP-MIX Progenitor Cells to
SDF-1-injected Mouse Spleen.
 
The mouse progenitor cell line
FDCP-MIX (20) was cultured in Fischer’s medium supple-
mented with 20% horse serum and 5% X-63–IL-3 conditioned
medium (21). To distinguish FDCP-MIX progenitor cells in
transplantation experiments from host progenitor cells, 15–20 
 
3
 
10
 
6
 
 FDCP-MIX cells were labeled with the fluorescent mem-
brane/dye PKH-26 (Sigma) following the instructions of the
manufacturer. In preliminary experiments, we determined that 72 h
after labeling, PKH-26-labeled FDCP-MIX cells could still be
detected by their fluorescent signal and distinguished from nonla-
beled host progenitor cells. For these series of experiments PKH-
26-labeled FDCP-MIX cells were plated in a modified colony as-
say containing 0.9% methylcellulose, IMDM, 20% horse serum,
2% X-63–IL-3-conditioned medium and 2 mM 
 
l
 
-Glutamine. At
72 h from initiation of the culture, clusters of approximately 32
cells were observed; all of them were also detected by fluores-
cence microscopy. After 72 h, the sensitivity in detecting fluores-
cent clusters was consistently reduced, owing to dilution of the
PKH-26 membrane dye into daughter cells (
 
.
 
5 cell divisions).
After 5 d of culture, all clusters had reached the size of colonies
(
 
.
 
50 cells) but had lost most of the initial detectable fluorescent
signal (data not shown). Female C57BL/6 mice were used as re-
cipients for transplantation. To deliver SDF-1 into their spleen,
the mice were anesthetized and the spleen carefully exposed
through a postero–lateral left incision. SDF-1 in PBS, MIP-1
 
a in
PBS, or PBS alone (75–100 ml vol) were injected intrasplenically
using an insulin needle. After the body wall was sutured, the mice
were injected intravenously with 2–3 3 106 FDCP-MIX cells la-
beled with PKH-26 as described above. 3 h after the injection,
the mice were sacrificed by CO2 inhalation and the spleens col-
lected. 5 3 105 splenocytes were plated in duplicate in the clono-
genic assay for FDCP-MIX described above. After 72 h, the
plates were scored by counting fluorescent colonies (z32 cells)
on an inverted fluorescent microscope and the number of FDCP-
MIX clonogenic progenitors per spleen calculated by correcting the
counts obtained in the assay for the total number of splenocytes.
Calcium Efflux Assay. Purified BM or PB CD341 cells (pu-
rity z95%) were loaded with Fluo-3 (Molecular Probes) (7 mm
in HBSS), for 20 min at 378C, then diluted 1:5 with RPMI and
further incubated for 20 min. After two washes, the cells (1 3
106/ml) were resuspended in Hepes-buffered saline (HS) contain-
ing 137 mM NaCl, 5 mM KCl, 1 mM Na2HPO4, 5 mM glucose,
1 mM CaCl2, 0.5 mM MgCl2, 1 g/l BSA, and 10 mM Hepes pH
7.4. The cells were then incubated for 10 min at 378C, vortexed,
and analyzed on a FACScanÒ for basal levels of fluorescence. Af-
ter stimulation with a chemokine, fluorescence changes were
monitored over time for up to 150 s. Data were analyzed by gat-
ing on low/SSC, medium/high FSC cells and calculating the
mean fluorescence intensity and the percentage of responding
cells (fluorescence above threshold) every 4 s.
Ex Vivo Culture of CD341 Cells. CD341 cells (0.4 3 106/
well) were plated in a 24-well plate in IMDM containing 10% FCS
containing 1025 M 2-ME, 2 mM l-Glutamin, 50 U/ml penicillin,
50 mg/ml Streptomycin in the presence of either rHu IL-3 (30 ng/
ml), rHu G-CSF (50 ng/ml), rHu SCF (100 ng/ml), or mouse
SDF-1 (100 ng/ml). After 18 h, cells were collected, washed once,
and subjected to a chemotaxis assay as described before. The per-
centage of migratory CD341 cells after culture in the presence of
the different cytokines was performed as described above.
Results
Stromal Cell–derived SDF-1 Is a Chemoattractant for Human
CD341 Progenitor Cells. We have used an in vitro chemo-
tactic  assay to study the migratory response of human
CD341 progenitor cells to different stimuli. Since cells of
the microenvironment of the BM may be involved in the
trafficking of HPC, we first assayed the chemotactic re-
sponse of CD341 cells to conditioned media from different
BM stromal cell lines. Conditioned media from MS-5 stro-
mal cells (22) and, to a lesser extent, from other BM stro-
mal cell lines (16), were able to induce the chemotaxis in
vitro of human CD341 progenitor cells (Fig. 1). Migratory
cells were evaluated both phenotypically by the expression
of CD34 and functionally by their ability to form hemato-
poietic colonies in methylcellulose assays (CFC).
In these initial experiments, it was determined that the
conditioned media of MS-5 cells also contained a chemo-
tactic activity for lymphocytes (17). Because lymphocytes
are more easily obtained and isolated than CD341 progeni-
tor cells, they were used as indicator cells during the purifi-
cation of chemoattractant activity(s) present in the condi-
tioned media of MS-5 stromal cells. The purification of this
activity was performed by sequential heparin, cation ex-
change, and reverse-phase HPLC chromatography. The
chemoattractant activity coeluted with a single protein
peak in reverse-phase HPLC and migrated as a single band
in SDS-PAGE of 8 kD (17). The protein was identified by
NH2-terminal sequencing (17) as SDF-1 (23–25). Electro-
spray and matrix-assisted laser desorption mass spectrome-114 A Chemotactic Factor for Hematopoietic Progenitors
try gave a mass that was consistent with that predicted for
SDF-1 (17). MS-5-derived SDF-1 purified to homogene-
ity-attracted human CD341 cells in vitro with similar effi-
cacy to the original MS-5-conditioned medium (Fig. 2 A).
At present, we do not know whether additional factors are
present in the MS-5-conditioned media that could also in-
duce chemotaxis of CD341 progenitor cells.
Purified human CB CD341 progenitor cells responded
in chemotactic assays to concentrations of SDF-1 as low
as 30 ng/ml. On average, 20% of the CD341 population
migrated to SDF-1 at the optimal concentration of 300 ng/ml
(Fig. 2 A). In contrast, no chemotactic response of CD341
cells was observed with other chemokines, including MIP-1a
(26), that can be produced by stromal cells and are well
documented to exert other effects than chemotaxis on
CD341 progenitor cells (27, 28; data not shown). The
presence of clonogenic progenitors among the CD341 cells
that migrated to SDF-1 was confirmed by CFC assays (Fig.
2 B). Both BFU-E erythroid and CFU-GM myeloid pro-
genitors present in the CD341 population exhibited a
marked chemotactic activity towards SDF-1. Their relative
proportions within the total CFC population did not
change after migration (compared with their relative pro-
portions in the input population), indicating that the effect
of SDF-1 is similar on both myeloid and erythroid progen-
itors. Multipotent clonogenic progenitors (CFU-MIX) were
also capable of chemotaxis in vitro to SDF-1, but their pro-
portion within the total CFC population was reduced by
50% after migration (data not shown; Fig. 2 B).
Figure 1. BM stromal cells produce a chemoattractant for human
CD341 progenitor cells. CD341 cells from human cord blood (CB) (2.0 3
105/well) were assayed for their capacity to migrate in a Boyden chamber
(5 mm bare filters), towards conditioned media from different BM stromal
cell lines. The migratory population was evaluated phenotypically as the
number of CD341 cells that migrated (left, open bars), and functionally as
the number of clonogenic progenitors (CFC) that migrated to the condi-
tioned media (right, closed bars). Bars and columns indicate the duplicate
and mean of one representative experiment out of three.
Figure 2. Stromal-derived SDF-1 is a chemoattractant for human and
mouse hematopoietic progenitor cells. (A) Chemotaxis assay of cord
blood (CB) CD341 cells in response to various concentration of SDF-1
(10, 30, 100, 300, 1,000 ng/ml). Results represent the average and the
range of three experiments performed in duplicates. Data are expressed as
the percent of input cells that migrated. The percentage of migration of
CB CD341 to undiluted MS-5 supernatant in the same experiments was
used as control and is shown as a bar diagram on the right (n 5 3). (B)
Chemotactic response to SDF-1 of clonogenic progenitors (CFC). The
graph shows the number of CFU-GM, BFU-E, and CFU-MIX progeni-
tors from human CB CD341 cells that migrated to 300 ng/ml of SDF-1
or control media in a chemotaxis assay. (C) Transendothelial chemotaxis
in vitro of human bone marrow (BM) or mobilized peripheral blood (PB)
CD341 cells in response to different concentration of SDF-1. Results
show the average and the range of three experiments performed in dupli-
cates. (D) Transendothelial chemotaxis of mobilized PB CD341 cells in
response to SDF-1 or to various chemoattractants and cytokines at the
concentrations described in the Materials and Methods. (E) Transendo-
thelial chemotaxis in vitro of the mouse progenitor cell lines FDCP-MIX
and M1 in response to SDF-1. (F). In vivo delivery of SDF-1 into mouse
spleens increases the seeding of intravenously transplanted FDCP-MIX
cells in this organ. Experimental mice were injected intrasplenically with
SDF-1 and control mice were injected with MIP-1a or with PBS and
then transplanted i.v. with PKH-26-labeled FDCP-MIX cells, as de-
scribed in Materials and Methods (three experimental mice and three
control mice per experiment; three separate experiments performed). 3 h
after the injection, mice were killed and 5 3 105 splenocytes plated in du-
plicate in a clonogenic assay for FDCP-MIX. After 72 h, the plates were
counted on an inverted fluorescent microscope and scored for the num-
ber of fluorescent colonies. Results show the significant increase in
FDCP-MIX clonogenic precursors per SDF-1 injected spleens relative to
control injected spleens. Data shown are from three experiments: *P ,0.005.115 Aiuti et al.
Migration across the sinusoidal endothelial barrier is an
important event in the trafficking of HPC inside or outside
the BM. We determined CD341 cells were capable of mi-
grating in a transendothelial assay. For these assays, we used
the mouse endothelial cell line b-End-3 (18). These cells
allowed simple and reproducible establishment of an ho-
mogeneous cells layer (90–95% confluence at the time of
the assay). Mouse endothelial cells have been used exten-
sively in the past to study adhesion and transmigration of
human leukocytes based on the high functional equivalence
of the majority of human adhesion molecules and their
mouse homologs (29–31). We found that both BM and
mobilized PB CD341 cells responded in a transendothelial
assay to SDF-1 at the optimal concentration of 100–300
ng/m (Fig. 2 C). Chemically synthesized SDF-1 elicited
optimal chemotactic response on these CD34 populations
at the same concentration range (data not shown). MCP-1,
MIP-1a, MIP-1b, IL-8, Rantes, eotaxin, and c-kit ligand
(SCF) were all ineffective in a similar assay (Fig. 2 D).
Moreover, SDF-1 elicited chemotaxis on the mouse
primitive progenitor cell line FDCP-MIX (20). 20% of the
input cells migrated to 100 ng/ml of SDF-1 (Fig. 2 E). In
contrast, the mouse myeloid progenitor cell line M1 (32)
showed no chemotactic response to the same concentration
of SDF-1.
To determine the ability of SDF-1 to attract progenitor cells
in vivo, we injected SDF-1 intrasplenically and measured
the lodging in the spleen of intravenously transplanted
FDCP-MIX progenitor cells. To distinguish transplanted
progenitor cells from the endogenous ones, FDCP-MIX
cells were labeled before injection with the membrane dye
PKH-26. The number of FDCP-MIX clonogenic precur-
sors that seeded in SDF-1-injected spleens was significantly
greater (2.5-fold; P ,0.005) than that found in PBS or
mMIP-1a-injected spleens from control mice (Fig. 2 F).
To test whether specific subpopulations of CD341 cells
had markedly different chemotactic responses to SDF-1,
we performed immunophenotyping of CD341 cells that
migrated towards SDF-1 and compared them with the in-
put CD341 population (Table 1). No changes were ob-
served in the proportion of more primitive CD341/DR2
or CD341/CD382 (33) cells after migration. Similarly,
CD341/CD331 cells (34), CD341/CD101 cells, (35), and
CD341/CD71 cells (36; data not shown), enriched for
myeloid, B, and T cell progenitors, respectively, were
equally represented in the input and migratory populations.
CD341 cells that migrated to SDF-1 were more enriched
in committed CD45RA1 cells (37); this enrichment was
more evident in PB than in BM CD341 cells.
We studied whether the action of SDF-1 on CD341
progenitors induced other responses (i.e., proliferation or
differentiation) in addition to chemotaxis. SDF-1 did not
display colony-stimulating factor activity on BM CD341
cells either alone, or in association with IL-3 or SCF, at the
concentrations of 50 and 200 ng/ml (data not shown).
SDF-1 Induces Calcium Mobilization and Pertussis Toxin-
dependent Chemotaxis in CD341 Cells.  Mobilization of in-
tracellular calcium is an early event in the response to
Table 1. Immunophenotype of CD341 Cells Migrating to SDF-1
CD341/CD382 CD341/HLA-DR2 CD341/CD45RA1 CD341/CD101 CD341/CD331
Input Migrated Input Migrated Input Migrated Input Migrated Input Migrated
BM 3.7 6 0.9 4.3 6 0.5 2.9 6 0.6 2.9 6 0.7 54.5 6 6 66.9 6 4.6 15.8 13.6 58.8 66.5
PB 6.5 3.5 1.38 1.07 31.1 67.8 2.6 6 1 3.0 6 0.9 83 6 10 79 6 9
CB 2.6 6 0.2 2.5 6 0.2 ND ND 30.5 46.1 ND ND ND ND
CD341 cells before migration (input) and CD341 cells that migrated to SDF-1 were analyzed for the expression of different markers by FACSÒ anal-
ysis. Numbers indicate the percentage of cells within each subset relative to total CD341 cells. BM, bone marrow; CB, cord blood; PB, peripheral
blood. Data without standard errors are from single experiments. Overall statistics for CD45RA staining P ,0.05.
Figure 3. SDF-1 induces calcium fluxes in human CD341 cells and the
associated chemotaxis is pertussis toxin sensitive. (A) SDF-1 induces cal-
cium fluxes in human CD341cells. Human BM CD341 cells were loaded
with the calcium-sensitive dye Fluo-3. Changes in Fluo-3 emission in re-
sponse to SDF-1 (30 ng/ml, open circles; 300 ng/ml, closed circles) or human
MCP-1 (300 ng/ml, open squares) were monitored over time by flow cy-
tometry. (B) The chemotaxis of human CD341 to SDF-1 is pertussis
toxin sensitive. The chemotactic response of human BM CD341 cells to
SDF-1 (300 ng/ml) after a 2-h incubation in 10% FCS IMDM with (100
ng/ml; pert toxin) or without pertussis toxin (control). Results shown are
the mean (and duplicates) of the percentage of the migration of the con-
trol samples (which are considered as 100%). Actual percentage of migra-
tion in the control ranged from 18–25% of input. Data are representative
of three separate experiments.116 A Chemotactic Factor for Hematopoietic Progenitors
chemokine signals (38). We tested the ability of SDF-1 to
induce modulation of calcium in human BM CD341cells
in a flow cytometric assay. SDF-1 (300 ng/ml) induced a
rapid, transient flux of intracellular calcium, which re-
turned to basal levels within 60 s (Fig. 3 A). No response
was elicited by human MCP-1 at either 300 ng/ml (Fig.
3 A) or 30 ng/ml (data not shown). The proportion of
CD341 cells fluxing calcium in response to SDF-1 ranged
between 15–25% (data not shown). Mobilized PB CD341
cells also showed a transient rise in intracellular calcium
upon SDF-1 stimulation (data not shown). To our knowl-
edge, these results demonstrate that human CD341 he-
matopoietic progenitor cells are capable of modulating in-
tracytoplasmatic calcium in response to an external ligand.
Chemokines induce calcium mobilization and chemo-
taxis upon interaction with specific receptors that are cou-
pled through heterotrimeric G proteins to signal-transduc-
ing pathways. To determine whether the response of CD341
cells to SDF-1 involved interaction(s) with a receptor that
was coupled to G proteins, we preincubated CD341 cells
with pertussis toxin, a potent inhibitor of Gai-proteins
(39). This pretreatment inhibited by 95% the transient flux
of intracellular calcium to SDF-1 (data not shown), as well
as abrogated almost completely the in vitro chemotactic re-
sponse of CD341 cells to SDF-1 (Fig. 3 B).
Mobilized PB CD341 Cells Are Less Responsive to SDF-
1-induced Chemotaxis than BM CD341 Cells. In current trans-
plantation protocols, CD341 progenitor cells resident in the
BM are currently mobilized to the PB for harvesting (40–
43) and subsequently used for transplantation (44). We
compared the chemotactic responses to SDF-1 of BM resi-
dent and mobilized blood circulating CD341 cells from pa-
tients receiving high dose chemotherapy and/or G-CSF
treatment. In a transendothelial assay, mobilized PB CD341
cells showed significantly lower chemotaxis (fourfold) than
their BM counterparts (Fig. 4). The lower proportion of
PB CD341 cells migrating in response to SDF-1 was found
at all concentrations of SDF-1 tested (data not shown; see
Fig. 2 C). The same result was found in one experiment
that was performed with BM and PB CD341 cells col-
lected from the same patient at the same timepoint after
mobilization (indicated as solid symbols in Fig. 4). These
results indicate that the lower response of PB CD341 cells
to SDF-1 correlates with their extramedullary location
rather than with an indirect effect of the mobilization re-
gime (which, in principle, should have had the same effect
on BM CD341 cells).
Chemotaxis of CD341 Cells to SDF-1 Is Enhanced by IL-3
ex vivo Treatment. Several cytokines, including IL-3, SCF,
G-CSF, and GM-CSF are known to mobilize hematopoie-
Figure 4. Mobilized PB CD341 cells are less responsive to SDF-1 in-
duced chemotaxis than their BM counterparts. PB samples were obtained
from solid tumor patients treated in the hematological recovery phase of
chemotherapy 1 G-CSF treatment (n 5 6, squares), or on day 5 of G-CSF
treatment alone (n 5 1, diamond), as described in Materials and Methods.
BM samples were obtained from normal donors (n 5 6; circles) or from
solid tumor patient in remission (n 5 1; square). Closed circles represent
one set of CD341 cells purified from BM or PB samples obtained the
same day of treatment from the same tumor patient treated in the hema-
tological recovery phase of chemotherapy 1 G-CSF treatment. Symbols
indicate the percentage of CD341 cells migrating to SDF-1 (300 ng/ml)
in a transendothelial assay. Each symbol represents one different prepara-
tion from a different donor. The horizontal bars indicate the average per-
centage of migration for the bone marrow and the mobilized peripheral
blood CD341cell samples, respectively. Data for PB CD341 cells are the
following: average 5.1% of input, SEM 0.58. Data for BM CD341 cells
are the following: average 20% of input, SEM 3.4; P ,0.01. The pro-
portion of cells migrating to control media in these transendothelial assays
ranged from 0.05 to 0.5% percent of input, resulting in a low accuracy in
detecting few cells (,1,000) by flow cytometry and a large variability of
chemotactic indexes (CI). Therefore, no statistically significant differences
were found between the CI of BM and PB CD341 cells to SDF-1, al-
though a tendency was observed for lower CI in PB CD341 cells (median
CI for BM CD341, 48 [SEM 8]; for PB CD341, 24 [SEM 16]).
Figure 5. Cytokine modulation of CD341 cell chemotaxis to SDF-1.
CD341 cells were incubated for 18 h in the presence of either 30 ng/ml
IL-3, 50 ng/ml G-CSF or 100 ng/ml SCF and assayed for transendothe-
lial chemotaxis in response to 300 ng/ml of SDF-1. Results show the
mean fold change in the chemotactic response of CD341 in three separate
experiments performed in duplicate, with respect to chemotaxis before
treatment (*P ,0.05).117 Aiuti et al.
tic progenitors to the peripheral blood (45). In view of the
finding described above that G-CSF-mobilized CD341
progenitors showed a reduced chemotactic response to
SDF-1, we studied whether this and other cytokines were
able to modify the response of CD341 cells to SDF-1 in
vitro. These experiments also possibly concern procedures
such as the stimulation of CD341 cells with cytokines in
vitro, which is essential for ex vivo survival and/or expan-
sion of HPC before transplantation (46–48), or the current
use of cytokines for facilitating retroviral-mediated gene
transfer into HPC (49). We tested whether an incubation
for 18 h with either IL-3, SCF, or G-CSF affected the
chemotaxis of human BM CD341 cells to SDF-1 (Fig. 5).
IL-3 induced a significant increase (2.2 fold) in the percent-
age of cells responding to SDF-1. Incubation of CD341
cells with SCF or G-CSF resulted in increased chemotaxis
of these cells to SDF-1 (1.4- to 1.9-fold), but which did
not reach statistical significance. A similar increase in che-
motactic activity after exposure to IL-3 was observed using
PB CD341 cells (data not shown).
Discussion
Here, we present evidence that hematopoietic progeni-
tor cells migrate in vitro and in vivo towards a gradient of a
chemotactic factor produced by stromal cells. This stromal
cell-derived chemotactic factor was identified as SDF-1 (23–
25) and is the first chemoattractant reported for human
CD341 progenitor cells. SDF-1, at the concentrations ef-
fective in chemotaxis assays, elicited a transient elevation in
the concentration of cytoplasmic calcium in CD341 cells.
Pertussis toxin inhibited SDF-1-induced chemotaxis, sug-
gesting that its signaling in CD341 cells is mediated by G
protein of the Gi class. SDF-1 was able to attract BFU-E,
CFU-GM, and CFU-MIX progenitor cells from human
BM, CB and mobilized PB. CD341 cells migrating to SDF-1
included cells with a more primitive (CD341/CD382 or
CD341/DR2) phenotype as well as CD341 cells commit-
ted to the lymphoid and myeloid lineages. The chemotac-
tic response of CD341 cells to SDF-1 is increased by expo-
sure to IL-3. Finally, the chemotactic response elicited by
SDF-1 on PB CD341 cells was lower than that found on
their BM counterparts.
Our experiments revealed that mouse SDF-1 elicits
transendothelial chemotaxis on human and mouse HPC
(Fig. 2). That mouse SDF-1 has activity on human CD341
progenitor cells is not surprising, because the amino acid
sequences of this molecule are highly conserved, with only
one amino acid difference between these two species (50).
Although SDF-1 is not specific for hematopoietic progeni-
tor cells, as it is also a chemoattractant for human lympho-
cytes and monocytes (17), it elicits rapid and direct chemo-
taxis of CD341 HPC. Other molecules have been shown
to elicit some chemotaxis and chemokinesis on mouse pro-
genitor cells, such as SCF (51). However, the input popu-
lation used for these experiments were total BM mononu-
clear cells, the percentage of migratory cells was very low
(z1%), and the maximum migration after exposure to SCF
occurred much later (8–24 h) than in conventional chemo-
taxis assays (2–4 h). These considerations make it difficult
to evaluate whether these effects were direct or indirect
and thus their significance. In contrast, our results indicate
that, (a) SDF-1 elicits maximal transendothelial migration
of z25% of the CD341 population 3 h after exposure (Fig.
2); (b) the same percentage of CD341 cells flux Ca21 rap-
idly (20 s) and transiently after exposure to SDF-1 (Fig. 3;
data not shown); and (c) migration is completely blocked
by pertussis toxin (Fig. 3).
Our data indicate that it is possible to increase signifi-
cantly (2.53) the number of mouse HPC lodged in the
spleen after in vivo administration of SDF-1 in this organ
(Fig. 2). There is increasing evidence that the homing of
HPC into hematopoietic organs requires the specific inter-
actions of selectins, integrins, and sugar receptors with their
ligands, but the mechanisms underlying these events re-
main largely unclear. Regardless of the specific adhesion
receptors involved in this process, we presume that activat-
ing chemotactic signals will be required, as they have been
demonstrated to be necessary for the migration of mature
leukocytes (11). In this context, it is conceivable that SDF-1
may facilitate and direct the migration of hematopoietic
progenitor cells from BM blood sinusoid to the hematopoi-
etic extravascular space. Although SDF-1 mRNA has been
found in all tissues examined in humans and in mice, it was
not found to be produced by hematopoietic cells (23, 25, 50).
During their maturation, hematopoietic progenitor cells
have been postulated to occupy physically separated niches
bordered with particular stromal cell types performing dis-
crete functions (8). It is intriguing to speculate that the
migration of progenitor cells from one niche to another
within the BM microenvironment involves gradients of
chemotactic factors, and that SDF-1 could be one of those
factors involved in the local trafficking of human CD341
cells. SDF-1 gradients could be generated by stromal cells
producing different amounts of the chemokine and/or of
chemokine-binding proteins, such as heparan sulfate. In
fact, we have previously observed different levels of SDF-1
mRNA in different stromal cell clones (16), and different
degrees of CD34 chemotaxis were also found in the condi-
tioned media of different stromal lines (Fig. 1; data not
shown).
Circulating PB HPC increase after chemotherapy and/or
after exogenous cytokines are administrated. The use of PB
CD341 HPC for autologous and allogeneic transplantation
has greatly increased in the past years (44). Mobilized PB
CD341 progenitor cells contain primitive progenitor cells
and display similar capacities to survive, proliferate, and dif-
ferentiate in vitro with respect to steady-state BM CD341
cells (52–54). In addition, their proliferative and differenti-
ation potential is demonstrated by the increasing number of
successful transplantations using PB CD341 HPC (3, 4, 41,
42). Therefore, the mobilization treatment does not impair
the viability, response to exogenous cytokines, proliferation,
and differentiation measured by the ability of CD341 cells
to form colonies in vitro or their ability to generate blood
cells in vivo. Therefore, there is no indication that mobi-118 A Chemotactic Factor for Hematopoietic Progenitors
lized CD341 cells are functionally compromised as a conse-
quence of the mobilization treatment. Accordingly, the PB
CD341 cells used for our studies form colonies in methyl-
cellulose assays in vitro at ratio comparable to their BM
counterparts (see Materials and Methods; data not shown).
Also, rapid neutrophil and platelet engraftment of PB
CD341 so far has been documented in three out of three
patients receiving PB HPC infusions for hematopoietic re-
constitution (see Materials and Methods; data not shown).
Yet, these functionally competent CD341 progenitors iso-
lated from PB collections showed a fourfold reduction in
their chemotactic activity to SDF-1 when compared with
BM resident CD341 cells. This finding was further con-
firmed in one experiment in which BM and PB CD341
cells were collected from the same patient at the same time-
point after mobilization. Downregulation of responsiveness
to SDF-1 may represent one mechanism by which CD341
HPC are aided in their movement from BM extravascular
space to the sinusoids and to the peripheral circulation.
G-CSF is the mobilizing agent most commonly used in
the clinic (44). In fact, the PB CD341 preparations used in
this study were obtained from patients that were treated
with G-CSF alone or in combination with chemotherapy.
However, after 18 h of incubation in vitro with G-CSF,
CD341 cells did not reduce or increase significantly their
chemotactic response to SDF-1 (Fig. 5). It is possible that
the effect of G-CSF in vivo may require a longer exposure
or it may involve the stromal microenvironment or other
BM cells, such as macrophages, lymphocytes, or precursor
cells (myelocytes, erythroblasts), which constituted only a
minor contaminant (,5%) of our CD341 cell preparations.
However, preexposure of CD341 cells to IL-3 induced a
twofold increase in the chemotactic response of CD341
cells to SDF-1. In the light of these results, it is of special
interest that (1) a short (16-h) ex vivo incubation with IL-3
enhances the engraftment of mouse (55), sheep, and ba-
boon HPC (56) into the BM of transplanted animals; (2)
IL-3 has been shown to enhance mobilization when used
in conjunction with G-CSF (45).
Although at present we do not know what the relevance
is in vivo of SDF-1 in the homing of CD341 to the mar-
row after transplantation or its involvement in the experi-
mental mobilization of CD341 cells, it is now clear that
SDF-1 is a chemokine with unique properties on CD341
hematopoietic progenitors, which may be of importance in
the homing of BM CD341 progenitor/stem cells to differ-
ent organs during development and to different niches
within the BM during differentiation and maturation of
HPC. Recent experiments showing that mice that have
been made genetically deficient in SDF-1 have normal (FL)
myelopoiesis but drastically impaired BM myelopoiesis (57)
suggest that, in fact, SDF-1 plays a critical role in the mi-
gration of HPC between the FL and the BM in vivo. Fur-
thermore, manipulation of SDF-1 may offer promising
ways to improve both transplantation and mobilization of
hematopoietic cells.
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